Cargando…
Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction
The lymphatic vasculature plays a critical role in a number of disease conditions of increasing prevalence, such as autoimmune disorders, obesity, blood vascular diseases, and cancer metastases. Yet, unlike the blood vasculature, the tools available to interrogate the molecular basis of lymphatic dy...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226566/ https://www.ncbi.nlm.nih.gov/pubmed/25383712 http://dx.doi.org/10.1371/journal.pone.0112548 |
_version_ | 1782343642761920512 |
---|---|
author | Agollah, Germaine D. Gonzalez-Garay, Manuel L. Rasmussen, John C. Tan, I-Chih Aldrich, Melissa B. Darne, Chinmay Fife, Caroline E. Guilliod, Renie Maus, Erik A. King, Philip D. Sevick-Muraca, Eva M. |
author_facet | Agollah, Germaine D. Gonzalez-Garay, Manuel L. Rasmussen, John C. Tan, I-Chih Aldrich, Melissa B. Darne, Chinmay Fife, Caroline E. Guilliod, Renie Maus, Erik A. King, Philip D. Sevick-Muraca, Eva M. |
author_sort | Agollah, Germaine D. |
collection | PubMed |
description | The lymphatic vasculature plays a critical role in a number of disease conditions of increasing prevalence, such as autoimmune disorders, obesity, blood vascular diseases, and cancer metastases. Yet, unlike the blood vasculature, the tools available to interrogate the molecular basis of lymphatic dysfunction/disease have been lacking. More recently, investigators have reported that dysregulation of the PI3K pathway is involved in syndromic human diseases that involve abnormal lymphatic vasculatures, but there have been few compelling results that show the direct association of this molecular pathway with lymphatic dysfunction in humans. Using near-infrared fluorescence lymphatic imaging (NIRFLI) to phenotype and next generation sequencing (NGS) for unbiased genetic discovery in a family with non-syndromic lymphatic disease, we discovered a rare, novel mutation in INPPL1 that encodes the protein SHIP2, which is a negative regulator of the PI3K pathway, to be associated with lymphatic dysfunction in the family. In vitro interrogation shows that SHIP2 is directly associated with impairment of normal lymphatic endothelial cell (LEC) behavior and that SHIP2 associates with receptors that are associated in lymphedema, implicating its direct involvement in the lymphatic vasculature. |
format | Online Article Text |
id | pubmed-4226566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42265662014-11-13 Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction Agollah, Germaine D. Gonzalez-Garay, Manuel L. Rasmussen, John C. Tan, I-Chih Aldrich, Melissa B. Darne, Chinmay Fife, Caroline E. Guilliod, Renie Maus, Erik A. King, Philip D. Sevick-Muraca, Eva M. PLoS One Research Article The lymphatic vasculature plays a critical role in a number of disease conditions of increasing prevalence, such as autoimmune disorders, obesity, blood vascular diseases, and cancer metastases. Yet, unlike the blood vasculature, the tools available to interrogate the molecular basis of lymphatic dysfunction/disease have been lacking. More recently, investigators have reported that dysregulation of the PI3K pathway is involved in syndromic human diseases that involve abnormal lymphatic vasculatures, but there have been few compelling results that show the direct association of this molecular pathway with lymphatic dysfunction in humans. Using near-infrared fluorescence lymphatic imaging (NIRFLI) to phenotype and next generation sequencing (NGS) for unbiased genetic discovery in a family with non-syndromic lymphatic disease, we discovered a rare, novel mutation in INPPL1 that encodes the protein SHIP2, which is a negative regulator of the PI3K pathway, to be associated with lymphatic dysfunction in the family. In vitro interrogation shows that SHIP2 is directly associated with impairment of normal lymphatic endothelial cell (LEC) behavior and that SHIP2 associates with receptors that are associated in lymphedema, implicating its direct involvement in the lymphatic vasculature. Public Library of Science 2014-11-10 /pmc/articles/PMC4226566/ /pubmed/25383712 http://dx.doi.org/10.1371/journal.pone.0112548 Text en © 2014 Agollah et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Agollah, Germaine D. Gonzalez-Garay, Manuel L. Rasmussen, John C. Tan, I-Chih Aldrich, Melissa B. Darne, Chinmay Fife, Caroline E. Guilliod, Renie Maus, Erik A. King, Philip D. Sevick-Muraca, Eva M. Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title | Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title_full | Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title_fullStr | Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title_full_unstemmed | Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title_short | Evidence for SH2 Domain-Containing 5′-Inositol Phosphatase-2 (SHIP2) Contributing to a Lymphatic Dysfunction |
title_sort | evidence for sh2 domain-containing 5′-inositol phosphatase-2 (ship2) contributing to a lymphatic dysfunction |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226566/ https://www.ncbi.nlm.nih.gov/pubmed/25383712 http://dx.doi.org/10.1371/journal.pone.0112548 |
work_keys_str_mv | AT agollahgermained evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT gonzalezgaraymanuell evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT rasmussenjohnc evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT tanichih evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT aldrichmelissab evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT darnechinmay evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT fifecarolinee evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT guilliodrenie evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT mauserika evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT kingphilipd evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction AT sevickmuracaevam evidenceforsh2domaincontaining5inositolphosphatase2ship2contributingtoalymphaticdysfunction |